scholarly journals Association Between T 2 * Relaxation Times Derived From Ultrashort Echo Time MRI and Symptoms During Exercise Therapy for Patellar Tendinopathy: A Large Prospective Study

2021 ◽  
Author(s):  
Stephan J. Breda ◽  
Robert‐Jan Vos ◽  
Dirk H. J. Poot ◽  
Gabriel P. Krestin ◽  
Juan A. Hernandez‐Tamames ◽  
...  
Keyword(s):  
Prospective Study ◽  
Exercise Therapy ◽  
Relaxation Times ◽  
Patellar Tendinopathy ◽  
Large Prospective Study ◽  
Ultrashort Echo Time ◽  
Echo Time

scholarly journals Measurement of bound and pore water T1 relaxation times in cortical bone using three-dimensional ultrashort echo time cones sequences

2016 ◽  
Vol 77 (6) ◽  
pp. 2136-2145 ◽  
Author(s):  
Jun Chen ◽  
Eric Y. Chang ◽  
Michael Carl ◽  
Yajun Ma ◽  
Hongda Shao ◽  
...  
Keyword(s):  
Cortical Bone ◽  
Pore Water ◽  
Relaxation Times ◽  
Three Dimensional ◽  
Ultrashort Echo Time ◽  
T1 Relaxation ◽  
Echo Time

scholarly journals Tissue‐Specific T 2 * Biomarkers in Patellar Tendinopathy by Subregional Quantification Using 3D Ultrashort Echo Time MRI

2020 ◽  
Vol 52 (2) ◽  
pp. 420-430 ◽  
Author(s):  
Stephan J. Breda ◽  
Dirk H.J. Poot ◽  
Dorottya Papp ◽  
Bas A. Vries ◽  
Gyula Kotek ◽  
...  
Keyword(s):  
Patellar Tendinopathy ◽  
Ultrashort Echo Time ◽  
Tissue Specific ◽  
Echo Time

scholarly journals Clinical application of ultrashort echo-time MRI for lung pathologies in children

2021 ◽  
Author(s):  
J. Geiger ◽  
K.G. Zeimpekis ◽  
A. Jung ◽  
A. Moeller ◽  
C.J. Kellenberger
Keyword(s):  
Clinical Application ◽  
Ultrashort Echo Time ◽  
Echo Time

PP-0120 Applicator visualization using ultrashort echo time MRI for HDR endorectal brachytherapy

2021 ◽  
Vol 158 ◽  
pp. S89-S90
Author(s):  
E. Kerkhof ◽  
R. van den Ende ◽  
E. Ercan ◽  
R. Keesman ◽  
C. Marijnen ◽  
...  
Keyword(s):  
Ultrashort Echo Time ◽  
Echo Time

scholarly journals Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Fulvia Pimpinelli ◽  
Francesco Marchesi ◽  
Giulia Piaggio ◽  
Diana Giannarelli ◽  
Elena Papa ◽  
...  
Keyword(s):  
Prospective Study ◽  
Polycythemia Vera ◽  
Essential Thrombocythemia ◽  
Active Treatment ◽  
Myeloproliferative Neoplasm ◽  
Large Prospective Study ◽  
Lower Response ◽  
Ongoing Treatment ◽  
Vaccine Immunogenicity

AbstractIn a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.

Sign in / Sign up

Export Citation Format

Share Document